Martee L. Hensley, Sara Kravetz, Xiaoyu Jia, Alexia Iasonos, William Tew, Lauren Pereira, Paul Sabbatini, Christin Whalen, Carol A. Aghajanian, Corinne Zarwan and Suzanne Berlin Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer Cancer 118
Article first published online: 20 SEP 2011 | DOI: 10.1002/cncr.26569
Eribulin produces objective responses in 5.5% of women with platinum-resistant, recurrent ovarian cancer and in 19% of women with platinum-sensitive disease. The median progression-free survival is 1.8 months in the platinum-resistant group and 4.1 months in the platinum-sensitive group.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.